

# Chenchen

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/9541361/chenchen-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

27  
papers

267  
citations

9  
h-index

15  
g-index

28  
ext. papers

371  
ext. citations

4.3  
avg, IF

3.01  
L-index

#	Paper	IF	Citations
27	Induction Chemotherapy Followed by Primary Tumor Resection Did Not Bring Survival Benefits in Colon Cancer Patients With Asymptomatic Primary Lesion and Synchronous Unresectable Metastases.. <i>Frontiers in Oncology</i> , <b>2022</b> , 12, 747124	5.3	0
26	Pharmacist-Led Management Improves Treatment Adherence and Quality of Life in Opioid-Tolerant Patients With Cancer Pain: A Randomized Controlled Trial.. <i>Pain and Therapy</i> , <b>2022</b> , 11, 241	3.6	
25	FOLFIRI (folinic acid, fluorouracil, and irinotecan) increases not efficacy but toxicity compared with single-agent irinotecan as a second-line treatment in metastatic colorectal cancer patients: a randomized clinical trial.. <i>Therapeutic Advances in Medical Oncology</i> , <b>2022</b> , 14, 17588359211068737	5.4	2
24	Amplification and expression of c-MET correlate with poor prognosis of patients with gastric cancer and upregulate the expression of PDL1. <i>Acta Biochimica Et Biophysica Sinica</i> , <b>2021</b> , 53, 547-557	2.8	2
23	Phase III trial comparing XELOX regimen (oxaliplatin plus capecitabine) versus EOX regimen (epirubicin, oxaliplatin and capecitabine) as first-line treatment for advanced gastric cancer: EXELOX trial.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 4014-4014	2.2	1
22	XELOX or mFOLFOX6 chemotherapy combined with resection of primary lesion versus chemotherapy alone for colon cancer with unresectable metastases: A randomized clinical trial.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 3590-3590	2.2	
21	Apatinib for patients with metastatic biliary tract carcinoma refractory to standard chemotherapy: results from an investigator-initiated, open-label, single-arm, exploratory phase II study. <i>Therapeutic Advances in Medical Oncology</i> , <b>2021</b> , 13, 17588359211039047	5.4	0
20	A prospective phase II study of raltitrexed combined with S-1 as salvage treatment for patients with refractory metastatic colorectal cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , <b>2021</b> , 17, 513-521	1.9	1
19	LncRNA SLCO4A1-AS1 Accelerates Growth and Metastasis of Gastric Cancer Regulation of the miR-149/XIAP Axis. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 683256	5.3	1
18	MiRNA-339-5p suppresses the malignant development of gastric cancer via targeting ALKBH1. <i>Experimental and Molecular Pathology</i> , <b>2020</b> , 115, 104449	4.4	19
17	miR-345 inhibits migration and stem-like cell phenotype in gastric cancer via inactivation of Rac1 by targeting EPS8. <i>Acta Biochimica Et Biophysica Sinica</i> , <b>2020</b> , 52, 259-267	2.8	4
16	Comparison of intravoxel incoherent motion imaging, diffusion kurtosis imaging, and conventional DWI in predicting the chemotherapeutic response of colorectal liver metastases. <i>European Journal of Radiology</i> , <b>2020</b> , 130, 109149	4.7	5
15	DNMT1 maintains the methylation of miR-152-3p to regulate TMSB10 expression, thereby affecting the biological characteristics of colorectal cancer cells. <i>IUBMB Life</i> , <b>2020</b> , 72, 2432-2443	4.7	6
14	Severe loss of visceral fat and skeletal muscle after chemotherapy predicts poor prognosis in metastatic gastric cancer patients without gastrectomy. <i>Journal of Cancer</i> , <b>2020</b> , 11, 3310-3317	4.5	8
13	UQCRC1 downregulation is correlated with lymph node metastasis and poor prognosis in CRC. <i>European Journal of Surgical Oncology</i> , <b>2019</b> , 45, 1005-1010	3.6	6
12	Comparison of efficacy and safety of second-line palliative chemotherapy with paclitaxel plus raltitrexed and paclitaxel alone in patients with metastatic gastric adenocarcinoma: A randomized phase II trial.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 4054-4054	2.2	1
11	Naturally Occurring Sesquiterpene Lactone-Santonin, Exerts Anticancer Effects in Multi-Drug Resistant Breast Cancer Cells by Inducing Mitochondrial Mediated Apoptosis, Caspase Activation, Cell Cycle Arrest, and by Targeting Ras/Raf/MEK/ERK Signaling Pathway. <i>Medical Science Monitor</i> , <b>2019</b> , 25, 3474-3482	3.2	2

10	PEGylated zinc oxide nanoparticles induce apoptosis in pancreatic cancer cells through reactive oxygen species. <i>IET Nanobiotechnology</i> , <b>2019</b> , 13, 536-540	2	4
9	Hepatocyte growth factor-induced mesenchymal-epithelial transition factor activation leads to insulin-like growth factor 1 receptor inhibitor unresponsiveness in gastric cancer cells. <i>Oncology Letters</i> , <b>2018</b> , 16, 5983-5991	2.6	4
8	Plasma microRNA-based signatures to predict 3-year postoperative recurrence risk for stage II and III gastric cancer. <i>International Journal of Cancer</i> , <b>2017</b> , 141, 2093-2102	7.5	11
7	Concordance of immune checkpoints within tumor immune contexture and their prognostic significance in gastric cancer. <i>Molecular Oncology</i> , <b>2016</b> , 10, 1551-1558	7.9	38
6	The Predictive and Prognostic Value of Early Metabolic Response Assessed by Positron Emission Tomography in Advanced Gastric Cancer Treated with Chemotherapy. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 1603-10	12.9	20
5	Effects of IGF2BP2, KCNQ1 and GCKR polymorphisms on clinical outcome in metastatic gastric cancer treated with EOF regimen. <i>Pharmacogenomics</i> , <b>2015</b> , 16, 959-70	2.6	20
4	Identification of short-form RON as a novel intrinsic resistance mechanism for anti-MET therapy in MET-positive gastric cancer. <i>Oncotarget</i> , <b>2015</b> , 6, 40519-34	3.3	14
3	Neutropenia predicts better prognosis in patients with metastatic gastric cancer on a combined epirubicin, oxaliplatin and 5-fluorouracil regimen. <i>Oncotarget</i> , <b>2015</b> , 6, 39018-27	3.3	11
2	Functional genetic approach identifies MET, HER3, IGF1R, INSR pathways as determinants of lapatinib unresponsiveness in HER2-positive gastric cancer. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 4559-73	12.9	53
1	The combination of RAD001 and MK-2206 exerts synergistic cytotoxic effects against PTEN mutant gastric cancer cells: involvement of MAPK-dependent autophagic, but not apoptotic cell death pathway. <i>PLoS ONE</i> , <b>2014</b> , 9, e85116	3.7	32